Pentax Canada Inc

WVU Cancer Institute Pioneers Esophageal Cancer Prevention with Cryoballoon Device

- WVU Cancer Institute is the first to commercially use the FDA-approved 180° C2 Cryoballoon for Barrett's esophagus treatment, a precancerous condition. - The Cryoballoon offers a targeted, minimally invasive cryotherapy, freezing and eliminating abnormal esophageal cells with enhanced precision and safety. - The technology represents a significant advancement in endoscopic treatments, providing new possibilities for at-risk patients and effective treatment options. - The first patient treated with the device experienced a quick recovery, demonstrating the potential for improved patient outcomes and reduced recovery time.